Effects of enalapril on clinical status, biochemistry, exercise performance and haemodynamics in heart failure.

abstract：:The number of effective cytotoxic agents for the treatment of patients with metastatic adult soft tissue sarcoma is limited, especially when patients have failed anthracycline- and ifosfamide-based chemotherapy. For the subgroup of patients with inoperable gastrointestinal stromal tumour (GIST), progress has been made...

journal_title：Drugs

authors： Hartmann JT,Patel S

更新日期：2005-01-01 00:00:00

abstract：UNLABELLED:Almotriptan is a selective serotonin 5-HT(1B/1D) receptor agonist ('triptan'). Its efficacy and tolerability have been assessed in a number of randomised, controlled trials in over 4800 adults with moderate or severe attacks of migraine. Oral almotriptan has a rapid onset of action (significant headache reli...

journal_title：Drugs

authors： Keam SJ,Goa KL,Figgitt DP

更新日期：2002-01-01 00:00:00

abstract：INTRODUCTION:Authorization of orphan medicinal products (OMPs) is often based on studies with several methodological shortcomings. Hence, data are difficult to interpret and efficacy does not always correspond to real-world effectiveness. We investigated to what extent an efficacy-effectiveness gap exists for OMPs for ...

journal_title：Drugs

authors： Schuller Y,Hollak CEM,Gispen-de Wied CC,Stoyanova-Beninska V,Biegstraaten M

更新日期：2017-09-01 00:00:00

abstract：:Pegylation of interferon-alpha-2a is associated with improved sustained virological response rates in patients with chronic hepatitis C. Subsequently, combination therapy with peginterferon-alpha-2a (40kD) [Pegasys] and ribavirin (Copegus trade mark, Rebetol) was investigated to establish if the efficacy of peginterfe...

journal_title：Drugs

authors： Keating GM,Curran MP

更新日期：2003-01-01 00:00:00

abstract：:The disposition of many drugs in cystic fibrosis is abnormal. In general, changes in pharmacokinetics include: increased volume of distribution, decreased plasma concentration, and enhanced renal and sometimes non-renal elimination of drugs. Pathophysiology of the disease important for drug disposition includes: (a) h...

journal_title：Drugs

authors： Prandota J

更新日期：1988-05-01 00:00:00

abstract：:Approximately 15% of patients with ulcerative colitis will experience a severe episode requiring hospitalization. Although intravenous corticosteroids are the current first-line therapy for these patients, about 30% of patients do not respond to corticosteroids and require either an alternative anti-inflammatory agent...

journal_title：Drugs

authors： Moss AC,Peppercorn MA

更新日期：2008-01-01 00:00:00

abstract：:Canagliflozin (Invokana™), an oral selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, is under global development with Mitsubishi Tanabe Pharma and Janssen Pharmaceuticals, a subsidiary of Johnson and Johnson, for the treatment of type 2 diabetes mellitus. SGLT2 are mainly located in the proximal tubule of t...

journal_title：Drugs

authors： Elkinson S,Scott LJ

更新日期：2013-06-01 00:00:00

abstract：:Lapatinib (Tyverb, Tykerb) is an orally active, small molecule, reversible, dual tyrosine kinase inhibitor of human epidermal growth factor receptor type 1 (HER1) and type 2 (HER2). In the EU, lapatinib in combination with capecitabine is indicated for the treatment of women with HER2-overexpressing, advanced or metas...

journal_title：Drugs

authors： Frampton JE

更新日期：2009-10-22 00:00:00

abstract：:Nivolumab (Opdivo(®)) is a fully human monoclonal antibody against programmed death receptor-1, a negative regulatory checkpoint molecule with a role in immunosuppression. The drug is administered intravenously and is approved for the treatment of unresectable malignant melanoma in Japan. The potential for intravenous...

journal_title：Drugs

authors： Deeks ED

更新日期：2014-07-01 00:00:00

abstract：:Enalapril provides significant haemodynamic, symptomatic and clinical improvement when added to maintenance therapy with digitalis and diuretics in patients with congestive heart failure [NYHA (New York Heart Association) classes II to IV]. These effects are not attenuated during long term therapy. More significantly,...

journal_title：Drugs

authors： Todd PA,Goa KL

更新日期：1989-02-01 00:00:00

abstract：:The incidence of adenocarcinoma of the pancreas has risen steadily over the past 4 decades. Since pancreatic cancer is diagnosed at an advanced stage, and because of the lack of effective therapies, the prognosis of such patients is extremely poor. Despite advances in our understanding of the molecular biology of panc...

journal_title：Drugs

authors： Rosenberg L

更新日期：2000-05-01 00:00:00

abstract：:Eplerenone (Inspra) is a selective aldosterone blocker. Oral eplerenone is approved for use in patients with left ventricular (LV) systolic dysfunction and clinical evidence of heart failure following acute myocardial infarction (MI) in the US and in European countries (e.g. the UK and The Netherlands). The addition o...

journal_title：Drugs

authors： Keating GM,Plosker GL

更新日期：2004-01-01 00:00:00

abstract：:Atherosclerosis can be defined in terms of the processes involved rather than in morphological terms, and there is evidence for possible roles of the macrophage in atherogenesis. The relevance of hyperlipidaemia to the morphogenesis of the atherosclerotic plaque is important, and this has been described in animal mode...

journal_title：Drugs

authors： Woolf N

更新日期：1988-01-01 00:00:00

abstract：:Torasemide (torsemide) is a high-ceiling loop diuretic which acts on the thick ascending limb of the loop of Henle to promote rapid and marked excretion of water, sodium and chloride. Like furosemide (frusemide), its major site of action is from the luminal side of the cell. Torasemide is at least twice as potent as f...

journal_title：Drugs

authors： Friedel HA,Buckley MM

更新日期：1991-01-01 00:00:00

abstract：:Azacitidine (Vidaza) is a pyrimidine nucleoside analogue of cytidine. Subcutaneous azacitidine was recently approved in the EU for the treatment of adults who are not eligible for haematopoietic stem cell transplantation and who have intermediate-2-risk or high-risk myelodysplastic syndromes (MDS) [according to Intern...

journal_title：Drugs

authors： Keating GM

更新日期：2009-01-01 00:00:00

abstract：:Aminoglycosides are potent water-soluble antibiotics, with peak concentration-dependent bactericidal activity against many pathogenic aerobic Gram-negative bacilli and Staphylococcus aureus. For systemic therapy, they must be given parenterally (intravenously or intramuscularly). In the body they remain largely extrac...

journal_title：Drugs

authors： Kumana CR,Yuen KY

更新日期：1994-06-01 00:00:00

abstract：:Drug-resistant tuberculosis (DR-TB) is an emerging global health threat as treatment involves complex multiple drug regimens, which are longer and more toxic than standard therapy and yet have worse outcomes. In the presence of resistance to one or more first-line drugs, an alternative regimen should be designed. A ma...

journal_title：Drugs

authors： Albanna AS,Menzies D

更新日期：2011-05-07 00:00:00

abstract：:Dementia is commonly diagnosed at a time of major domestic breakdown, when symptoms are severe and family and community patience has been eroded. In order to encourage early referral and identification of patients with treatable conditions, a Memory Clinic is held at the University Hospital in Cardiff. The clinic prov...

journal_title：Drugs

authors： Bayer AJ,Pathy MS,Twining C

更新日期：1987-01-01 00:00:00

abstract：:Lung tissue remodelling in chronic inflammatory lung diseases has long been regarded as a follow-up event to inflammation. Recent studies have indicated that, although airway and lung tissue remodelling is often independent of inflammation, it precedes or causes inflammation. None of the available therapies has a sign...

journal_title：Drugs

authors： Roth M

更新日期：2015-01-01 00:00:00

abstract：:Dapoxetine, a selective serotonin reuptake inhibitor, is the first oral pharmacological agent indicated for the treatment of men aged 18-64 years with premature ejaculation. In four randomized, double-blind, placebo-controlled, multicentre studies of 12-24 weeks' duration, oral dapoxetine 30 or 60 mg (administered as ...

journal_title：Drugs

authors： Hoy SM,Scott LJ

更新日期：2010-07-30 00:00:00

abstract：:Second-generation histamine H1 receptor antagonists (antihistamines) have been developed to reduce or eliminate the sedation and anticholinergic adverse effects that occur with older H1 receptor antagonists. This article evaluates second-generation antihistamines, including acrivastine, astemizole, azelastine, cetiriz...

journal_title：Drugs

authors： Slater JW,Zechnich AD,Haxby DG

更新日期：1999-01-01 00:00:00

abstract：:Type 2 diabetes mellitus is a progressive and complex disorder that is difficult to treat effectively in the long term. The majority of patients are overweight or obese at diagnosis and will be unable to achieve or sustain near normoglycaemia without oral antidiabetic agents; a sizeable proportion of patients will eve...

journal_title：Drugs

authors： Krentz AJ,Bailey CJ

更新日期：2005-01-01 00:00:00

abstract：:Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV‑2), is now a global pandemic. This virus primarily affects the respiratory tract and causes lung injury characterized by acute respiratory distress syndrome. Although the pathophysiology of COVID-19 is not yet clea...

journal_title：Drugs

authors： Hajra A,Mathai SV,Ball S,Bandyopadhyay D,Veyseh M,Chakraborty S,Lavie CJ,Aronow WS

更新日期：2020-10-01 00:00:00

abstract：:Sotagliflozin (Zynquista™) is the first dual inhibitor of sodium-glucose co-transporter-1 and -2 (SGLT1 and 2). In the phase 3, inTANDEM 1-3 trials, adjunctive use of oral sotagliflozin (200 mg or 400 mg once daily) improved glycaemic control and reduced bodyweight and insulin requirements relative to placebo over 24 ...

journal_title：Drugs

authors： Deeks ED

更新日期：2019-12-01 00:00:00

abstract：:Azimilide is a potassium channel antagonist that, in contrast to existing class III antiarrhythmic agents, blocks both the rapidly (I(Kr)) and slowly (I(Ks)) activating components of the delayed rectifier potassium current. In animal and clinical studies, azimilide prolonged repolarisation by increasing the action pot...

journal_title：Drugs

authors： Clemett D,Markham A

更新日期：2000-02-01 00:00:00

abstract：:Gemfibrozil improves lipid and apolipoprotein profiles, particularly very low density lipoprotein (VLDL) triglyceride and high density lipoprotein (HDL) cholesterol levels, in patients with dyslipidaemia when administered at a total daily dose of 900 or 1200 mg. As demonstrated by the Helsinki Heart Study, these effec...

journal_title：Drugs

authors： Spencer CM,Barradell LB

更新日期：1996-06-01 00:00:00

abstract：:A multicentre clinical trial was carried out to determine the activity and tolerability of ofloxacin in the treatment of lower respiratory tract infections. 667 patients were randomly allocated to 1 of 3 different twice daily dosage regimens: 400 mg (245 patients), 600 mg (211) or 800 mg (211). The mean duration of tr...

journal_title：Drugs

authors： Grassi C,Gialdroni Grassi G,Mangiarotti P

更新日期：1987-01-01 00:00:00

abstract：:Viral conjunctivitis is one of the most common disorders observed in ophthalmic emergency departments, yet no established treatment exists. Lately, antiviral medications have been introduced into clinical practice; however, a systematic review focusing on their use and effectiveness in the treatment of viral conjuncti...

journal_title：Drugs

authors： Skevaki CL,Galani IE,Pararas MV,Giannopoulou KP,Tsakris A

更新日期：2011-02-12 00:00:00

abstract：:Interstitial lung disease (ILD) can be associated with all connective tissue diseases and is an important cause of morbidity and mortality. The management of connective tissue disease-interstitial lung disease (CTD-ILD) is challenging due substantial heterogeneity in disease behaviour and paucity of controlled clinica...

journal_title：Drugs

authors： Jee AS,Corte TJ

更新日期：2019-09-01 00:00:00

abstract：:Entecavir (Baraclude) is a novel nucleoside analogue of 2'-deoxyguanosine whose intracellular triphosphate form inhibits replication of the hepatitis B virus (HBV). In large, randomised, double-blind, phase III clinical trials in patients with chronic HBV infection, oral entecavir 0.5 or 1.0mg once daily for up to 96 ...

journal_title：Drugs

authors： Robinson DM,Scott LJ,Plosker GL

更新日期：2006-01-01 00:00:00